Jiangsu Recbio Technology Co., Ltd. Class H (2179) AI Stock Analysis

• Market Cap: HK$4.02B
• Dividend Yield: N/A
• Average Volume (3M): 20.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.37
• Revenue Growth: N/A
• EPS Growth: 3.30%
• Country: HK
• Employees: 531
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.71
• Shares Outstanding: 316,138,700
• 10 Day Avg. Volume: 13,400
• 30 Day Avg. Volume: 20,716
• PEG Ratio: 4.50
• Price to Book (P/B): 6.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: HK$8.00 ▼(-5.88%Downside)

The overall stock score is primarily influenced by the company's challenging financial performance, which is the most significant factor. Moderate technical analysis and poor valuation further weigh down the score, reflecting the high-risk nature of the investment.

Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.

How the Company Makes Money

Jiangsu Recbio Technology Co., Ltd. generates revenue through the development and sale of its vaccine products. The company invests in research and development to create innovative vaccines, which are then commercialized and distributed to healthcare providers and institutions. Revenue streams include sales of approved vaccines, licensing agreements, and potential collaborations with other pharmaceutical companies and research institutions. The company may also receive funding from government contracts or grants for vaccine development, contributing to its revenue.

Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview

Summary

The company faces significant financial challenges with declining revenue, persistent losses, and negative cash flows. High leverage and negative equity in some periods pose additional risks, indicating a precarious financial position.

Income Statement

The income statement reveals a challenging financial position. Revenue has decreased from 2023 to 2024, indicating a negative growth trend. Gross Profit Margin is positive, but Net Profit Margin is significantly negative due to substantial net losses, reflecting high operational costs and inefficiencies. The company is experiencing negative EBIT and EBITDA Margins, highlighting ongoing operational challenges and lack of profitability.

Balance Sheet

The balance sheet indicates moderate risk. The company has a negative equity position in some past years, which has improved slightly but remains vulnerable. High Debt-to-Equity ratios suggest significant leverage, posing financial risk. The Return on Equity (ROE) is negative, reflecting continued losses. However, the company maintains a reasonable level of assets relative to liabilities, providing some stability.

Cash Flow

Cash flow analysis shows a concerning trend. Operating cash flow is consistently negative, reflecting cash outflows from operations. Free Cash Flow is also negative, indicating that the company is not generating sufficient cash to cover capital expenditures. The lack of positive cash flow growth suggests ongoing financial strain and limited liquidity.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
27.00M	30.38M	5.33M	6.20M	1.46M
	Gross Profit
15.95M	22.34M	5.33M	6.20M	1.46M
	EBIT
-571.85M	-617.75M	-735.97M	-612.46M	-147.67M
	EBITDA
-523.97M	-569.87M	-847.67M	-590.00M	-134.91M
	Net Income Common Stockholders
-562.39M	-571.96M	-719.20M	-702.67M	-211.13M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
448.31M	837.76M	1.33B	1.18B	681.71M
	Total Assets
1.94B	2.19B	2.31B	1.92B	1.05B
	Total Debt
889.10M	650.79M	282.63M	76.72M	26.13M
	Net Debt
570.05M	-184.19M	-1.04B	-1.11B	-329.70M
	Total Liabilities
1.41B	1.12B	656.53M	245.92M	2.06B
	Stockholders Equity
529.32M	1.07B	1.66B	1.67B	-1.01B
Cash Flow		Free Cash Flow
-636.66M	-862.18M	-888.04M	-710.79M	-241.07M
	Operating Cash Flow
-464.82M	-638.07M	-579.54M	-472.92M	-70.34M
	Investing Cash Flow
-279.04M	9.42M	-378.43M	68.70M	-258.59M
	Financing Cash Flow
218.06M	275.27M	839.44M	1.23B	680.38M

Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Positive. The current price of 8.5 is above the 20-day moving average (MA) of 8.45, above the 50-day MA of 8.11, and above the 200-day MA of 8.33, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 52.68 is Neutral, neither overbought nor oversold. The STOCH value of 87.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2179.

Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.25B	3.27	-44.35%	6.27%	16.79%	-0.10%
2179	45 Neutral	HK$4.02B	―	-69.97%	―	―	3.30%
PIAIF		$126.07B	6.27		7.38%	―	―
SBMFF		$12.03B	49.32	6.14%	1.59%	―	―
SHTDF		$7.33B	6.95	9.19%	4.30%	―	―
WXIBF		$13.32B	28.61	8.17%	―	―	―
1873	58 Neutral	HK$3.45B	19.55	4.47%	―	-9.75%	―

Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events

Jiangsu Recbio Technology Announces 2024 AGM with Key Resolutions

Jiangsu Recbio Technology Co., Ltd. has announced its 2024 Annual General Meeting scheduled for June 20, 2025, where various resolutions will be considered, including financial reports, profit distribution plans, and changes in business scope. The meeting’s outcomes could significantly impact the company’s strategic direction and stakeholder interests, particularly with resolutions on share issuance and amendments to the Articles of Association.

Jiangsu Recbio to Boost Market Presence with H Share Full Circulation Plan

Jiangsu Recbio Technology Co., Ltd. has announced its participation in the H Share Full Circulation Plan, aiming to convert 141,953,490 unlisted shares into H shares. This strategic move is expected to significantly increase the company’s H share count to 94.85% of its total share capital, enhancing liquidity and potentially strengthening its market position on the Hong Kong Stock Exchange.

Jiangsu Recbio Announces Board Composition and Roles

Jiangsu Recbio Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders to understand the leadership dynamics and decision-making processes.

Jiangsu Recbio Advances Vaccine Development with Promising Clinical Trials

Jiangsu Recbio Technology Co., Ltd. announced significant advancements in its vaccine development pipeline for the year ending December 31, 2024. The company is progressing with Phase III clinical trials for its HPV 9-valent vaccine, which aims to address cervical cancer and genital warts, and is on track to submit a BLA application in 2025. Additionally, the company has completed enrollment for its shingles vaccine trial and is conducting follow-up studies to evaluate its efficacy and safety. The development of a bivalent recombinant respiratory syncytial virus vaccine is also underway, with preclinical studies expected to conclude in 2025. These developments position Jiangsu Recbio as a leading player in China’s vaccine industry, potentially impacting public health outcomes and offering new solutions for disease prevention.

Jiangsu Recbio Confirms Qualification of Joint Company Secretary

Jiangsu Recbio Technology Co., Ltd. has announced that Ms. CHEN Qingqing is now qualified to serve as the company’s secretary without needing further waivers from the Hong Kong Stock Exchange. Despite this qualification, the company will continue to employ a joint company secretary arrangement to ensure effective management, with Ms. YUNG Mei Yee assisting Ms. CHEN in her duties.